MARIMEKKO CORPORATION – REPURCHASE OF OWN SHARES ON 18 JULY 2018

Marimekko Corporation, Stock Exchange Release, 18th July 2018 at 18:45 EETMARIMEKKO CORPORATION – REPURCHASE OF OWN SHARES ON 18 JULY 2018AttachmentMarimekko trades 180718xlsx

MARIMEKKO OYJ – OMIEN OSAKKEIDEN HANKINTA 18.7.2018

Marimekko Oyj, Pörssitiedote 18.7.2018 klo 18.45MARIMEKKO OYJ – OMIEN OSAKKEIDEN HANKINTA 18.7.2018NASDAQ HelsinkiLiiteMarimekko trades 180718xlsx

Sonoco Declares Regular Quarterly Common Stock Dividend

HARTSVILLE, S.C., July 18, 2018 -- The Board of Directors of Sonoco (NYSE:SON) today declared a $.41 per share quarterly common stock dividend. The dividend will be paid on September 10, 2018, to shareholders of record as of August 10, 2018.According to Rob Tiede, president and chief executive...

GLOBAL BIOENERGIES : HALF-YEAR REPORT ON THE LIQUIDITY CONTRACT AS OF 29/06/2018

HALF-YEAR REPORT ON THE LIQUIDITY CONTRACT AS OF 29/06/2018Evry (France) - 18 July, 2018 - Global Bioenergies (Alternext Paris: ALGBE) presents the half-year report on the liquidity contract entrusted to the brokerage firm Gilbert Dupont. The following assets appeared on the liquidity account as of...

GLOBAL BIOENERGIES : BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITE AU 29/06/2018

BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITE AU 29/06/2018Evry (France), le 18 juillet 2018 - Global Bioenergies (Euronext Growth : ALGBE) présente le bilan semestriel du contrat de liquidité confié à la Société de Bourse Gilbert Dupont. Au 29 juin 2018, les moyens suivants figuraient au compte...

Novartis Kisqali® now first and only CDK4/6 inhibitor indicated in US as first-line therapy specifically for premenopausal women; and as initial therapy with fulvestrant in postmenopausal women

Kisqali is now the only CDK4/6 inhibitor indicated in combination with an aromatase inhibitor as first-line treatment for pre-, peri- or postmenopausal women with HR+/HER2- advanced breast cancer in the US[1] Kisqali is the only CDK4/6 inhibitor that is indicated with fulvestrant as both initial...

Foresight 4 VCT plc - Annual Financial Report

FORESIGHT 4 VCT PLCFinal Results18 July 2018Foresight 4 VCT plc, managed by Foresight Group CI Limited, today announces the final results for the year ended 31 March 2018.These results were approved by the Board of Directors on 18 July 2018.You may, in due course, view the Annual Report in full at...

Freedom Leaf Enters Discussions with Buyers for European Hemp Harvest; Details Strategic Advantages Toward Expedited Growth

LAS VEGAS, July 18, 2018 -- via OTC PR WIRE—Freedom Leaf, Inc. (OTCQB:FRLF), a Company dedicated to health and wellness products derived from legal Hemp and comprised of a group of diversified, international, vertically-integrated hemp businesses and cannabis media companies, is pleased to...